Randomized phase III study of TS-1 alone versus TS-1 plus CDDP in advanced gastric cancer

Trial Profile

Randomized phase III study of TS-1 alone versus TS-1 plus CDDP in advanced gastric cancer

Completed
Phase of Trial: Phase III

Latest Information Update: 21 Jan 2017

At a glance

  • Drugs Gimeracil/oteracil/tegafur (Primary) ; Cisplatin
  • Indications Gastric cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms SPIRITS
  • Sponsors Taiho Pharmaceutical
  • Most Recent Events

    • 21 Jan 2017 Results (n=1248) of a combined analysis from SPIRITS, TOP-002 and START trials, presented at the 2017 Gastrointestinal Cancers Symposium
    • 01 Jul 2008 Status changed from in progress to completed as reported by ClinicalTrials.gov.
    • 01 Mar 2008 Results published in Lancet Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top